Abstract:Background Major heart failure (HF) trials remain insufficient in terms of assessing the differences in clinical characteristics, biomarkers, treatment efficacy and safety due to the underrepresantation of women. The study aimed to present sex-related disparities in HF management, including differences in demographics, comorbidities, cardiac biomarkers, prescribed medications, and treatment outcomes. Method The study utilized anonymized data from the Turkish Ministry of Health's National Electronic Database between January 1, 2016, and December 31, 2022. The cohort analysis included 2,501,231 adult patients with HF. Specific therapeutic combinations were analyzed using a Cox-regression model to obtain relative risk reduction for all-cause death. The primary endpoint was all-cause mortality. Results Among the cohort, 48.7% (n=1 218 911) were male, while 51.3% (n= 1 282 320) were female. Female patients exhibited a higher median age (71 years vs. 68 years) and manifested higher prevalence of diabetes mellitus, anemia, atrial fibrillation, anxiety, and ischemic stroke. Male patients demonstrated higher rates of prior myocardial infarction, dyslipidemia, chronic obstructive pulmonary disease, and chronic kidney disease. Higher concentrations of natriuretic peptides were observed in female patients. RASi, beta blockers, MRAs, SGLT2i, and ivabradine were more commonly prescribed in male patients, whereas loop diuretics, digoxin, and ferric carboxymaltose were more frequent in females. Male patients had higher rates of CRT and ICD implantation rates. All-cause mortality and hospitalization rates were higher in male patients. Compared to monotherapy, all combinations, including SGLT2i, showed a beneficial effect on all-cause mortality in both female and male HF patients. In hospitalized HF patients, the addition of digoxin to RASi, MRAs, and beta blockers was superior to monotherapy regarding all-cause mortality in female HF patients compared to male HF patients. Conclusions In conclusion, this study highlights that sex-specific responses to HF medication combinations compared to monotherapy and differences in comorbidities underscore the importance of tailored management strategies. Digoxin showed a contrasting effect on all-cause mortality between both sexes in after hospitalization, while SGLT2i exhibited a consistent beneficial effect in both sexes when added to all combinations.

Navigating Heart Failure: Unveiling Sex Disparities in Guideline-Directed Medical Therapy Combinations